Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Stephen R. Broderick, MD, MPHS

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study Thomas.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer Marco Alifano, MD, PhD, Pierre.

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Survival after resection of synchronous non–small cell lung cancer

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Use of Amiodarone After Major Lung Resection

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

It's not “just a shunt” but sometimes it should be…

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response.

Stephen R. Broderick, MD, MPHS

Get it right the first time

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Adjuvant Chemotherapy Is Associated with Improved Survival after Esophagectomy without Induction Therapy for Node-Positive Adenocarcinoma Paul J. Speicher,

Lymphovascular Invasion in Non–Small-Cell Lung Cancer: Implications for Staging and Adjuvant Therapy Kristin A Higgins, MD, Junzo P Chino, MD, Neal Ready,

It’s All in the “Swerve of the Curve”

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Pulmonary Resection for Metastases from Colorectal Cancer

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Primary Small Cell Carcinoma of the Esophagus

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Multifocal lung cancer within ground glass lesions: Are favorable outcomes consequent to surgical resection or inherent to the disease? Mara B. Antonoff,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for.

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Presentation transcript:

Persistent N2 disease after neoadjuvant chemotherapy for non–small-cell lung cancer Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W. Onaitis, MD, Mark F. Berry, MD, Thomas A. D’Amico, MD, Chris R. Kelsey, MD The Journal of Thoracic and Cardiovascular Surgery Volume 142, Issue 5, Pages 1175-1179 (November 2011) DOI: 10.1016/j.jtcvs.2011.07.059 Copyright © 2011 Terms and Conditions

Figure 1 Outline of patients and treatment administered after neoadjuvant chemotherapy. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 1175-1179DOI: (10.1016/j.jtcvs.2011.07.059) Copyright © 2011 Terms and Conditions

Figure 2 Kaplan-Meier curve demonstrating overall survival (OS), disease-free survival, and local control for entire cohort of patients with persistent N2 disease after neoadjuvant chemotherapy. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 1175-1179DOI: (10.1016/j.jtcvs.2011.07.059) Copyright © 2011 Terms and Conditions

Figure 3 Kaplan-Meier curve demonstrating overall survival (OS) for patients with persistent N2 disease undergoing resection versus nonoperative treatment. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 1175-1179DOI: (10.1016/j.jtcvs.2011.07.059) Copyright © 2011 Terms and Conditions